Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Year-over-year operating cash flow growth rate
Percentile
P31
Within normal range
vs 3Y Ago
-0.3x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -43.68% |
| Q2 2025 | -20.44% |
| Q1 2025 | 37.14% |
| Q4 2024 | -30.51% |
| Q3 2024 | 29.21% |
| Q2 2024 | -162.54% |
| Q1 2024 | -124.22% |
| Q4 2023 | 59.54% |
| Q3 2023 | 38.00% |
| Q2 2023 | -9.69% |
| Q1 2023 | -155.13% |
| Q4 2022 | -168.81% |
| Q3 2022 | 145.92% |
| Q2 2022 | 22.39% |
| Q1 2022 | 6.04% |
| Q4 2021 | -4.97% |
| Q3 2021 | 15.10% |
| Q2 2021 | -4.76% |
| Q1 2021 | -27.41% |
| Q4 2020 | -21.11% |
| Q3 2020 | -38.76% |
| Q2 2020 | -49.05% |
| Q1 2020 | -241.53% |
| Q4 2019 | 77.93% |
| Q3 2019 | -13.37% |
| Q2 2019 | -115.19% |
| Q1 2019 | -58.00% |
| Q4 2018 | -266.98% |
| Q3 2018 | -61.34% |
| Q2 2018 | -18.99% |
| Q1 2018 | 89.17% |
| Q4 2017 | -113.56% |
| Q3 2017 | 1190.51% |
| Q2 2017 | 21.97% |
| Q1 2017 | 39.52% |
| Q4 2016 | -8.12% |
| Q3 2016 | 7.68% |
| Q2 2016 | -0.35% |
| Q1 2016 | -4.46% |
| Q4 2015 | -95.51% |